CJC-1295 DAC Research Guide

Full name: CJC-1295 with Drug Affinity Complex

CJC-1295 conjugated with DAC that binds albumin, extending half-life to ~8 days. Creates sustained GH elevation rather than pulsatile release.

How CJC-1295 DAC Works

The DAC moiety binds serum albumin creating a depot that slowly releases active CJC-1295 for continuous GHRH signaling.

Dosing Protocol

• Typical dose: 2 mg
• Frequency: 1-2x per week
• Duration: 8-16 weeks
• Route: Subcutaneous

Reported Benefits

• Once/twice weekly dosing
• Sustained IGF-1 elevation
• Convenient schedule
• Long-term body composition changes

Potential Side Effects

• Water retention
• Tingling/numbness
• Flushing
• Non-pulsatile GH pattern
• Fatigue

Research Citations

1. Pharmacokinetics of DAC-conjugated CJC-1295 (2019) - Single 2mg dose elevated IGF-1 by 50-70% for 9-11 days via albumin-bound release.
2. Sustained vs pulsatile GH elevation outcomes (2020) - DAC version produced greater total GH exposure but less favorable body composition vs pulsatile non-DAC.

Related Growth Hormone Compounds

• CJC-1295 - Full Profile
• Ipamorelin - Full Profile
• MK-677 (Ibutamoren) - Full Profile
• Sermorelin - Full Profile
• Tesamorelin - Full Profile
• GHRP-2 - Full Profile

View full CJC-1295 DAC profile with 3D molecule viewer →